Eledon Pharmaceuticals
ELDN
29 hedge funds and large institutions have $16.5M invested in Eledon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
35% more capital invested
Capital invested by funds: $12.2M → $16.5M (+$4.26M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
4% more funds holding
Funds holding: 28 → 29 (+1)
0.04% less ownership
Funds ownership: 37.87% → 37.83% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$507K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$119K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$32.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$220K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
-$132K |
| 3 |
SFG
SVB Financial Group
Dallas,
Texas
|
-$18.5K |
| 4 |
Two Sigma Advisers
New York
|
-$17.9K |
| 5 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
-$13.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $335 | +$19 | +14 | +8% |
|
27
Group One Trading
Chicago,
Illinois
| $40 | -$6.71K | -4,828 | -100% |
|
28
Bank of America
Charlotte,
North Carolina
| $27 | +$21 | +15 | New |
|
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$220K | -158,099 | -100% |
|
|
SFG
30
SVB Financial Group
Dallas,
Texas
| – | -$18.5K | -13,472 | Closed |
|
|
31
Two Sigma Advisers
New York
| – | -$17.9K | -13,100 | Closed |
|
|
CRC
32
Curi RMB Capital
Chicago,
Illinois
| – | -$13.7K | -10,000 | Closed |
|
ELDN Hedge Fund Activity: Q4 2023 in Review
29 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2023, worth a combined $16.5M — up 35% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ELDN positions and 3 closed out — a net gain of 2 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, adding an estimated $507K. The largest seller was Royal Bank of Canada, cutting an estimated $220K.
- 29 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2023, up from 28 in Q3 2023.
- Funds reported $16.5M of Eledon Pharmaceuticals stock for Q4 2023, up 35% quarter-over-quarter.
- 5 funds opened new Eledon Pharmaceuticals positions in Q4 2023 and 3 closed out, a net change of +2 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $507K added.
- The largest Eledon Pharmaceuticals seller in Q4 2023 was Royal Bank of Canada, an estimated $220K sold.
Based on aggregated 13F filings for Q4 2023.